Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07276776 · ClinicalTrials.gov registry record · NA

An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

A NA study of Type 2 Diabetes Mellitus, sponsored by Insulet Corporation.

Active
Registry status
NA
Development phase
40
Enrollment target
6
Study locations

NCT07276776: Active NA study of Type 2 Diabetes Mellitus, sponsored by Insulet Corporation.

NCT07276776 is a NA study of Type 2 Diabetes Mellitus that is active but no longer recruiting, run by Insulet Corporation. The registered enrollment target is 40 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07276776, a NA study of Type 2 Diabetes Mellitus, is active but no longer recruiting, sponsored by Insulet Corporation.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
6
Study locations

Study Summary

This is a single arm feasibility study to evaluate the Omnipod M System in adults with Type 2 Diabetes with the aim to enroll to 40 participants aged 18-75 years with type 2 diabetes to have a minimum of 20 participants initiate the use of Omnipod M System and the goal of 16 participants completing the 6-week treatment period.

Primary Outcome

Glucose metric from study continuous glucose monitoring system

Conditions Studied

Interventions

  • DEVICE Omnipod M system

Study Locations (6)

Massachusetts

  • Joslin Diabetes - Boston
  • MassResearch LLC. - Waltham

Texas

  • Texas Diabetes and Endocrinology (TDE) - Austin
  • Disease & Glandular Disease Clinic - San Antonio

Michigan

  • Henry Ford Health - Detroit

North Carolina

  • Mountain Area Health Educational Center ( MAHEC) - Asheville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-12-12
Est. Completion 2026-02-27
Phase NA
Insulet Corporation

16 total trials

What the registry record for NCT07276776 still lists

NCT07276776 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Omnipod M system is the first listed.

NCT07276776 lists 6 locations in 4 states (Massachusetts, Texas, Michigan).

Frequently Asked Questions

What is clinical trial NCT07276776 about?

NCT07276776 is a clinical study titled "An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes". This is a single arm feasibility study to evaluate the Omnipod M System in adults with Type 2 Diabetes with the aim to enroll to 40 participants aged 18-75 years with type 2 diabetes to have a minimum of 20 participants initiate the use of Omnipod M System and the goal of 16 participants completing ...

What is the current status of trial NCT07276776?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-12-12. Estimated completion is 2026-02-27.

What conditions does trial NCT07276776 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT07276776?

The interventions under investigation include: Omnipod M system (DEVICE).

Who is sponsoring clinical trial NCT07276776?

This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07276776 being conducted?

This trial has 6 study locations across Massachusetts, Michigan, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07276776's enrollment target sits among peer trials

40 84th of 130 higher than 46 of 130 other Type 2 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07276776, the US trial registry maintained by the National Library of Medicine. NCT07276776 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.